Review Article
Chemotherapy Treatment Considerations in Metastatic Breast Cancer
Kirollos Hanna,(1) PharmD, BCPS, BCOP, and Kelley Mayden,(2) MSN, FNP, AOCNP®
From (1)Mayo Clinic and M Health Fairview, Rochester, Minnesota; (2)Ballad Health Cancer Care-Bristol, Bristol, Tennessee
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Kirollos Hanna, PharmD, BCPS, BCOP, 200 First St. SW, Rochester, MN 55905. E-mail: kirollos11@gmail.com
J Adv Pract Oncol 2021;12(suppl 2):6–12 |
https://doi.org/10.6004/jadpro.2021.12.2.11 |
© 2021 Harborside™
ABSTRACT
Historically, metastatic breast cancer (MBC) was primarily treated with surgery and chemotherapy. To that end, a wide array of chemotherapy agents are currently available for the treatment of MBC. To date, there has been considerable progress in the understanding of the molecular underpinnings of breast cancer, which has led to the development of targeted agents. Despite this, eventually all patients with metastatic disease will receive single-agent or combination chemotherapy either to control spread or as a palliative measure. Currently, combinations of targeted agents and chemotherapy are under investigation, thereby indicating that chemotherapeutic agents will continue to be the backbone of future breast cancer therapy. However, there remains an unmet need to optimize the sequencing of chemotherapy agents based on individual patient characteristics and gene expression profiles in order to reduce toxicities and improve outcomes for patients.
For access to the full length article, please
sign in.
